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Abstract
Background: Trachoma, caused by Chlamydia trachomatis (Ct), is the leading infectious cause of blindness. Sequence-based
analysis of the multiple strains typically present in endemic communities may be informative for epidemiology,
transmission, response to treatment, and understanding the host response.
Methods: Conjunctival and nasal samples from a Gambian community were evaluated before and 2 months after mass
azithromycin treatment. Samples were tested for Ct by Amplicor, with infection load determined by quantitative PCR
(qPCR). ompA sequences were determined and their diversity analysed using frequency-based tests of neutrality.
Results: Ninety-five of 1,319 (7.2%) individuals from 14 villages were infected with Ct at baseline. Two genovars (A and B)
and 10 distinct ompA genotypes were detected. Two genovar A variants (A1 and A2) accounted for most infections. There
was an excess of rare ompA mutations, not sustained in the population. Post-treatment, 76 (5.7%) individuals had Ct
infection with only three ompA genotypes present. In 12 of 14 villages, infection had cleared, while in two it increased,
probably due to mass migration. Infection qPCR loads associated with infection were significantly greater for A1 than for A2.
Seven individuals had concurrent ocular and nasal infection, with divergent genotypes in five.
Conclusions: The number of strains was substantially reduced after mass treatment. One common strain was associated
with higher infection loads. Discordant genotypes in concurrent infection may indicate distinct infections at ocular and
nasal sites. Population genetic analysis suggests the fleeting appearance of rare multiple ompA variants represents purifying
selection rather than escape variants from immune pressure. Genotyping systems accessing extra-ompA variation may be
more informative.
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Introduction
Trachoma is the leading infectious cause of blindness worldwide
[1]. Repeated infection by Chlamydia trachomatis provokes chronic
follicular conjunctivitis (clinically active trachoma), which leads to
conjunctival scarring, entropion, trichiasis and ultimately blinding
corneal opacification. Trachoma is a major public health problem
affecting some of the world’s poorest regions. Current estimates
indicate 84 million have active trachoma, with 7.6 million visually
impaired from trachomatous corneal opacification [2]. The World
Health Organization is leading a global effort to control blinding
trachoma through the implementation of the SAFE Strategy:
Surgery for trichiasis, Antibiotics to reduce the burden of
chlamydial infection, and face washing and environmental
improvements to limit transmission [3].
Endemic trachoma is caused by 4 of the 19 recognised serovars
of C.trachomatis: A, B, Ba and C. Serovars are distinguished from
each other on the basis of surface variations in the Major Outer
Membrane Protein (MOMP). As the main antigenic target for
strain specific humoral immunity to C.trachomatis, MOMP has been
considered a vaccine candidate [4]. MOMP is encoded by the
ompA gene, which contains four variable segments (VS) inter-
spersed between five conserved segments (CS). Comparative
genome sequence analysis has indicated considerable variation in
ompA, possibly driven by host immune pressure, and the study of
ompA variants may therefore be informative in disease settings [5,6]
Originally serovars were distinguished according to their recog-
nition by panels of patient sera, however the ompA sequence motifs
for each serovar have now been well characterised. Organisms
assigned to a serovar group on the basis of their ompA sequence are
referred to here as genovars.
OmpA genotyping has been used previously to investigate
C.trachomatis infections in trachoma endemic populations [7–14],
usually with the goal of better understanding C.trachomatis
transmission. However the analysis of ompA sequence variation is
also relevant to the utility of MOMP as a target for chlamydial
vaccine development. In genital infections caused by C.trachomatis
D-K genovars, evidence that genovar and strain variants associate
with clinically important differences in the biology of infection is
marginal [15], and has not been described in human ocular
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The Gambian Government/Medical Research Council Joint
Ethics Committee (SCC 856) and the London School of Hygiene
and Tropical Medicine Ethics Committee approved the study. All
subjects, or their guardians, gave written informed consent, or
witnessed consent by thumbprint where appropriate.
Clinical Assessment
This study was conducted in 14 trachoma endemic Gambian
villages, located within a defined geographical area [16,17,18]. The
villages were surveyed and a population census was conducted.
Individuals normally resident in the study area for at least 6 months
of theyearwereenrolled. At baseline the entire available population
was examined for signs of trachoma and classified using the WHO
Trachoma Grading System [19]. A swab sample was collected from
the upper tarsal conjunctiva of each subject for DNA isolation and
kept cool until frozen at 220uC later the same day. Swabs of fresh
nasal discharge were collected.
Antibiotic Treatment
Following baseline clinical assessment, all participants were
offered antibiotic treatment. Adults and children over 6 months
old were given a single oral dose of azithromycin (20mg/kg up to a
maximum of 1g). Infants under 6 months were given tetracycline
eye ointment (twice daily, 6 weeks). All villages were examined and
treated within a 9 day period [17].
Follow-up
Two months after baseline assessment and antibiotic treatment,
participants were re-examined, and conjunctival and nasal
discharge samples again collected. Between these two time points,
the census was updated weekly, together with records of




CT/NG kit (Roche) [16]. Amplicor extracts from specimens with
detectable C.trachomatis DNA were further purified and concentrat-
ed using the QIAamp DNA Mini Kit (Qiagen) [16]. Infection load
was estimated by quantitative real-time PCR for the chlamydial
ompA gene using a previously described method [20].
ompA Sequencing
Sequencing of ompA used primers spanning VS1-4 and
sequences were comfirmed by a second sequencing pass. A
1076bp fragment was amplified using primers 87: 59 - TGA ACC
AAG CCT TAT GAT CGA CGG - 39 and 1163: 59 - CGG AAT
TGT GCA TTT ACG TGA G - 39. If no amplified product was
visible on an agarose gel, nested PCR was performed, with primers
87 (above) and 1059: 59 - GCA AGA TTT TCT AGA TTT CAT
C-3 9 used to amplify a 972bp target sequence. PCR products
were purified using the QIAquick PCR purification kit (Qiagen)
and sequenced using BigDye Terminator Cycle Sequencing
Ready Reaction kit V3.1(Applied Biosystems) with outer primers
97: 59 - CTT ATG ATC GAC GGA ATT TTC TAT GGG - 39
and 1047: 59 - GAT TTT CAT GAT TTC ATC TTG TTC
AAC TG - 39. Sequencing with inner primers 608: 59 - CTC TCT
GGG AAT GTG GGT GT - 39 and 627: 59 - ACA CCC ACA
TTC CCA GAG AG - 39 was performed to close sequencing gaps.
Sequences were edited and aligned using DNA*DNASTAR 5.07
(DNASTAR), with HAR 13 (NC_007429) as genovar A reference
and M33636 for genovar B. Here, a genotype denotes an ompA
sequence variant differing from the ompA reference sequence or
from another variant by one or more single nucleotide
substitutions, and is identified using the letter of its genovar and
an arbitrary number.
Analysis
Data were analysed in Stata 9.0, with differences in loads per
genotype examined using a two tailed t-test on logtransformed
loads. Sequence alignments were imported into DNAsp4.00 and
Tajima’s D value calculated [21,22]. P-values for each D test were
calculated using 10,000 coalescent simulations without the
presence of recombination to calculate the proportion of D values
generated which were greater than the observed D value. D* and





sampled and treated. At two-months 1344 (85%) were examined and
sampled. The overall prevalence of active trachoma in children
,10 years was 16% before and 12% two months after treatment,
with marked variations in prevalence between villages [16].
C. trachomatis Infection
The prevalence of C.trachomatis infection was 7.2% (95/1319)
before treatment and 5.7% (76/1344) two months after treatment.
Of individuals infected at baseline, 30% were still infected two
months after treatment and of those infections detected at two
months 36/66 (59%) occurred in subjects uninfected at baseline
(Table 1). Most infections (74/76; 97%) detected two months after
treatment were in two villages. Almost all residents of these two
Author Summary
Trachoma is an important cause of blindness resulting
from transmission of the bacterium Chlamydia trachomatis.
One way to understand better how this infection is
transmitted and how the human immune system controls
it is to study the strains of bacteria associated with
infection. Comparing strains before and after treatment
might help us learn if someone has a new infection or the
same one as before. Identifying differences between
disease-causing strains should help us understand how
infection leads to disease and how the human host
defences work. We chose to study variation in the
chlamydial gene ompA because it determines the protein
MOMP, one of the leading candidates for inclusion in a
vaccine to prevent trachoma. If immunity to MOMP is
important in natural trachoma infections, we would expect
to find evidence of this in the way the strains varied. We
did not find this, but instead found that two common
strains seemed to cause different types of disease.
Although their MOMPs were very slightly different, this
did not really explain the differences. We conclude that
methods of typing strains going beyond the ompA gene
will be needed to help us understand the interaction
between Chlamydia and its human host.
Chlamydial Genotypes in Trachoma
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treatment. This travelling event was very strongly associated with
infection at two months [16]. In contrast, in the other 12 study
villages all cases of C.trachomatis infection found at baseline had
resolved by two months and there were only 2 new cases of
infection in previously uninfected individuals.
ompA genotypes
77/95 (81%) baseline and 64/76 (84%) two-month ocular
C.trachomatis samples yielded sequence data. On both occasions
sequence data were obtained from all 5 Amplicor-positive nasal
specimens. 73 (95%) of the baseline ocular sequences were
genovar A and 4 (5%) were genovar B. Overall, ten separate
genotypes were identified; 8 genovar A and 2 genovar B. Sequence
variation compared to reference strains is shown in Table 2. For
most genotypes single nucleotide polymorphisms (SNPs) resulted
in amino acid changes in the variable sequence domains of
MOMP. Within genovar A baseline sequences, there were eight
polymorphic sites, of which five contained singletons (SNPs found
only in a single isolate). Tajima’s D value for baseline genovar A
sequences was 21.06, revealing trend towards an excess of rare
mutations, (p=0.16). This was supported by significantly negative
D* and F* indices, indicating an excess of singleton mutations
amongst genovar A sequences (22.59; P=0.02 and 2 2.45;
P=0.02 respectively). Only four genovar B sequences were found,
therefore frequency based analyses could not be performed.
However, addition of these four sequences to the genovar A
sequences for calculation of an overall Tajima’s D value revealed a
significant excess of rare mutations within the baseline dataset as a
whole (D=21.76 ; p=0.018).
Genotype distribution
Genotype frequencies are presented in Table 3. The dominant
strain, A2, accounted for 74% of baseline ocular isolates. All other
strains, except A1, were detected in only a few individuals. The 14
villages contained 79 family compounds (fenced areas inhabited
usually by the members of one extended family). 16 (20%)
contained subjects infected at baseline. Seven compounds
contained multiple strains; three of which had 3 strains and one
5 different strains. Obvious environmental risk factors which might
explain this concentration of diversity were not identified: however
the latter compound had an unusually high proportion of its
children attending the local primary school (7/25; 28%) compared
to (30/773: 4%) in the study area generally.
Genotypes following treatment
At two months post-treatment only three strains A1, A2 and A5
were found. The A2 proportion increased to 90%. Rare strains
had mostly disappeared. In 23 individuals ocular samples yielded
sequence data at both time points. 18 (78%) of these had the same
strain at both timepoints: 3 A1, 14 A2 and 1 A5 (the only example
of A5 at either timepoint). 5 (22%) showed a change in genotype:
from A1 to A2 in three cases, from A3/A4 to A2 in one case each.
34/35 (97%) newly infected individuals at two-months had the A2
genotype.
Genotypes and infection load
Infection load data from this population has been previously
described [16,17]. Geometric mean infection loads for strains A1
and A2 were compared by unpaired, two-sided t-tests on
logarithmically transformed data. Chlamydial load was signifi-
cantly higher in A1 infections before mass treatment: geometric
mean for A1 5809 copies (95% CI 374–90189) (n=6) and for A2
92 copies (95% CI 59–144) (n=14) (p,0.0001). Similarly, after
mass treatment geometric mean for A1 was 343 copies (95% CI
Table 1. Comparative ocular C. trachomatis infection status
(by Amplicor) before and two months after antibiotic




+ 27 60 87
2 39 1030 1069
Total 66 1090 1156
(+ infected, 2 not infected).
doi:10.1371/journal.pntd.0000306.t001
Table 2. Chlamydia trachomatis strains identified in this study.
Genovar A strain VS1 VS1 CS2 CS2 VS2 VS2 CS4 VS4 VS4
Genovar B
strain VS2
Nucleotide 278 289 304 353 505 523 790 991 1020 511
Ref A (HAR13) T (V) G (E) G (A) C (A) G (G) A (I) A A (T) G Ref B (M33636) G(G)
A1 .. . . . .G . .B 1 A ( G RS)
A2 .. A ( A RT ) ..C ( I RL) G . A B2
A3 .. A ( A RT ) ..C ( I RL) G . .
A4 . ..... G G ( T RA) .
A5 A( V RE) C (ERQ) . . A (GRS) . G . .
A6 .. A ( A RT) T (ARV) . C (IRL) G . A
A7 .. A ( A RT ) ... G .A
A8 . ..... G .A
Only single nucleotide polymorphisms and their locations are shown. Reference strains are C. trachomatis HAR 13 (genovar A) (NC_007429) and C. trachomatis M33636
(genovar B). Letters in parenthesis represent the amino acid and any resulting change. Genotype B2 is identical to the reference strain. (VS, variable sequence. CS,
conserved sequence.)
doi:10.1371/journal.pntd.0000306.t002
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(n=19) (p=0.0021). At both baseline and two-months, subjects
infected with A1 were more likely than those infected with A2 to
have clinically active disease: baseline: 7/10 vs 6/57 (RR=6.65,
x
2=15.63, p,0.0001); two-months 3/5 vs 7/58 (RR=4.97
p=0.025 2-tailed Fisher’s Exact Test). We have previously found
that infected individuals with clinical signs of trachoma have
higher chlamydial loads than those without signs [16,17]. These
analyses are not adjusted for potential clustering by village:
however A1 only occurred in one village (village 3).
Nasal genotypes
C trachomatis was detected in nasal samples from 5/58 subjects at
baseline, and from 5/54 at two months. In seven subjects ompA
sequence was determined in both ocular and nasal samples at the
same time point: 5/7 (71%) had different genotypes at the two
sites: A1(ocular)/A2 (nasal) in three cases, with A1(ocular)/
A3(nasal) and A2 (ocular)/A7(nasal) in one each. Differing
genotypes were found in all four individuals in whom baseline
ocular and two-month nasal ompA sequence were both determined,
and in the two individuals in whom baseline nasal and two-month
ocular ompA sequences were both determined.
Discussion
In this study, 972 bp sequences comprising almost the entire
C.trachomatis ompA gene were determined in samples from infected
individuals in a trachoma endemic area. Previous trachoma
studies have sequenced primarily VS regions: variation in the
interspersing ‘conserved’ segments is recognised but not usually
examined at the pathogen population level. All variants were
confirmed with double pass sequencing methods: dubious calls on
the chromatogram were all clarified by resequencing. We discuss
the utility of ompA genotyping for determining the existence and
nature of selection pressure on the locus, for examining whether
variants affect the features of infection or disease, and for
distinguishing causes of reemergent infection after treatment.
Ten C.trachomatis genotypes were identified at baseline. Except-
ing B2, these differed from strains previously sequenced from The
Gambia and elsewhere [7–11,13]. Before treatment most (87%)
infections were one of two strains (A1 and A2). Six of the minority
genovar A strains had SNPs resulting in amino acid changes
within variable segment domains. A similar pattern of a few
dominant strains with several other strains present at low
frequency has been described previously [7,10,14]. The variety
of strains in this limited geographical area might suggest that new
strains are regularly introduced through mixing with other
populations or alternatively that the emergence of new variants
is promoted by pressure from the human immune response. To
test this frequency based analyses of polymorphism were carried
out.
Population genetic analysis of baseline genovar A ompA
sequences showed negative Tajima’s D, Fu and Li’s D* and F*
statistics, suggesting that in this environment novel genovar A
ompA mutations are being eliminated from the population. Despite
this, the location of some of the polymorphic sites is intriguing. In
genotype A5 the neutralizing antibody epitope which defines
serovar A (
70DVAGLEK
76) is significantly altered
(
70DEAGLQK
76): previously we noted significant alteration in
close proximity to this epitope (
69(SRR)DVAGLEK
76) in strains
which subsequently failed to establish themselves in the commu-
nity [10]. One would expect that novel mutations which allow
immune evasion offer the pathogen a selective advantage (at least
while these strains remain uncommon), and ought to spread
through the pathogen population until they reach intermediary
frequencies. The excess of rare mutations observed at baseline
therefore does not support the hypothesis that ompA polymor-
phisms are maintained within this population by immune selection
pressure. Instead it implicates either ongoing negative selection
(where most mutations are deleterious and removed from the
population by purifying selection) or a recent selective sweep
(whereby a single haplotype has reached fixation within the
population, driving out diversity at the locus). Few studies have
applied population genetic methods to analyse selection of
C.trachomatis genes, but they have similarly generated little evidence
that ompA is under immune selection pressure: both cross sectional
studies of genovar A ompA sequences from Tanzania and sequence
analysis of genital Ct genovars have found similar evidence of
purifying selection in ompA [11,24] These data and the existence of
individuals within trachoma endemic communities who are often
or repetitively infected with the same ompA genovar lead us to
question whether the ompA locus is a target of selective pressure in
trachoma populations, and consequently whether targeting
MOMP will lead to an effective vaccine.
Strain-specific differences affecting infection or disease mani-
festations are described in genital chlamydial infection, but not
previously in trachoma. On both occasions strain A1 was
associated with clinical signs of active trachoma and with higher
mean infection loads to a greater extent than A2, but it was less
common in the community and so not necessarily a more
successful pathogen. The sampling method used here has been
shown elsewhere to give adequate yields of host RNA [18], but the
infection loads were not standardised, for example against host
DNA yield in the sample. In natural infections the number of cells
sampled, the proportion of host cells which are infected and the
state of the chlamydial developmental cycle within them will all
affect the measured load, and the best way to standardise the
measurements is not clear. A1 and A2 might amplify differently by
PCR, although there was no support for this suggestion in the
amplification of standards, and no variation affecting primer
binding sites. Differences in sampling, in PCR amplification or in
the infection/disease course within the sampled individuals might
explain this observation, or alternatively it could result directly or
indirectly from variation in ompA .
Table 3. Frequency of C. trachomatis strains present at
baseline and 2 months, subdivided by site of collection.











A1 10 (13) 5 (8) - 1 (20)
A2 57 (74) 58 (90.5) 4 (80) 3 (60)
A3 2 (2.5) - 1 (20) -
A4 1 (1.3) - - -
A5 1 (1.3) 1 (1.5) - -
A6 1 (1.3) - - -
A7 ---1 ( 2 0 )
A8 1 (1.3) - - -
B1 1 (1.3) - - -
B2 3 (4) - - -
doi:10.1371/journal.pntd.0000306.t003
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which two cause non-synonymous amino acid substitutions. These
might alter the conformation of MOMP or have direct effects on
‘fitness’, transmission or the host response. The GRA mutation at
position 304 introduces a cleavage motif for cathepsin-L, which
generates of peptide fragments for antigen presentation [25,26].
Whether peptide fragments of A1 and A2 MOMP are therefore
presented differently during the generation of adaptive cellular
immunity is unknown. Alternatively, strain differences might be
unrelated to ompA itself but reflect linkage between ompA genotype
and polymorphism(s) elsewhere on the chlamydial chromosome
leading to differences in fitness or metabolic advantage. Trachoma
strains may differ in their laboratory properties, and a recent study
found differences in in vitro growth rate, interferon-c sensitivity and
virulence in non-human primates [27], attributable to variation
affecting 22 open reading frames(ORFs) in addition to ompA. Both
clinical differences between strains, and the purifying selection at
the ompA locus could result from variation or selection pressure at
linked chlamydial ORFs.
Following mass antibiotic treatment there was a modest
reduction in the prevalence of infection [17]. Only 3 of the
original 10 genotypes were still present. Most (90.5%) of these
infections were with A2, and almost all in two villages (1 and 3 in
Table 4), in which the prevalence of infection actually increased
[17], with strains A1 and A2 continuing to dominate. New
infections, 97% with strain A2, were strongly associated with travel
to a festival in Senegal, at which over a million people from the
region congregated in basic conditions, where the opportunity to
acquire ocular C.trachomatis infection was probably considerable.
These data suggest that a remarkable re-infecting exposure to
strain A2 occurred in the treated subjects during this event. The
persistence of the common A1 or A2 strains in 17 individuals in
these villages could be due to treatment failure or to reinfection
facilitated by the same unusually effective environment for
C.trachomatis transmission. Genotyping provides some evidence
that antibiotic treatment was not 100% effective, as strain A5 was
found twice, but in the same individual both before and after
treatment, strongly suggesting primary treatment failure. Never-
theless antibiotic treatment cleared all baseline infections in the
other 12 villages [17].
The surprising demonstration of discordant genotypes in
concurrent ocular and nasal samples may imply that these two
mucosal surfaces function as distinct sites of infection, despite
direct communication via the nasolacrimal duct. This could result
from differences in the time course of infection or in the route of
inoculation. Autoreinfection of the conjunctiva from extraocular
sites such as the nasal mucosa has been suggested, however, a
study from Tanzania did not support this hypothesis [28]. Here,
the limited nasal genotyping data does not provide support
significant transmission between eye and nose.
Our study illustrates the use and limitations of ompA sequence
data in the molecular epidemiology of C.trachomatis infection. The
pattern of ompA sequence diversity remains intriguing and
inconsistent with immune selection pressure. Typing systems
including other polymorphic loci may lead to better elucidation of
key events in ocular C.trachomatis infection. An ongoing extended
longitudinal study of C.trachomatis genotypes might better define
the population dynamics, and determine implications for the long-
term success of mass treatment [14].
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Table 4. Clinical activity, infection (Amplicor) and genotypes by village and timepoint.
BASELINE 2 MONTHS
Village Examined TF/TI CT+ Genotypes Examined TF/TI CT+ Genotypes
1 142 25 20 A2(17) A5(1) 145 21 19 A2(11) A5(1)
2 97 2 0 - 97 2 2 A2(2)
3 115 18 41 A1(10) A2(19) A3(2) A4(1) 105 16 55 A1(5) A2 (45)
4 255 14 8 A2(5) 277 9 0 None
5 107 6 0 - 126 10 0 None
6 39 6 2 A2(1) B2(1) 37 1 0 None
7 86 0 1 - 83 0 0 None
8 83 3 1 - 77 6 0 None
9 23 0 0 - 21 1 0 None
10 60 4 0 - 57 2 0 None
11 97 5 0 - 93 1 0 None
12 103 14 0 - 98 5 0 None
13 53 0 0 - 64 1 0 None
14 58 6 22 A2(14) A6(1) A8(1) B1(1)
B2(2)
64 4 0 None
For each village, ‘Examined’ is the number of people examined ‘TF/TI’ is the number of individuals (all ages) with active trachoma, and ‘CT+’ the number of those whose
ocular swabs tested positive by Amplicor. The numbers bracketed after the genotype indicate the number of times it appeared: A2 (14) denotes 14 samples contained
genotype A2.
doi:10.1371/journal.pntd.0000306.t004
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